Daniel Karp is one of our independent directors. Mr. Karp is currently appointed Senior Vice President, Head of Business Development for Organon & Co., a wholly owned subsidiary of Merck & Co., scheduled to spin off as a separate company in 2021. Previously, Mr. Karp served as Executive Vice President, Corporate Development at Biogen Inc. from June 2018 to March 2020. Prior to joining Biogen Inc., Mr. Karp held a number of positions of increasing responsibility at Pfizer Inc., including as Vice President, Worldwide Business Development and Head of Business Development for Worldwide Research and Development from May 2016 to June 2018, as Vice President, Worldwide Business Development and Business Development Lead for Pfizer Vaccines, Oncology and Consumer Healthcare from January 2014 to May 2016, as Senior Director, Worldwide Business Development from December 2010 to December 2013, as Director, Worldwide Business Development from January 2008 to December 2010, as Senior Manager, Worldwide Business Development from May 2007 to December 2007, and as Manager, U.S. Business Development from July 2006 to April 2007. Prior to that, Mr. Karp held roles in healthcare and life sciences strategy consulting. Mr. Karp holds a Master of Business Administration from the Wharton School of the University of Pennsylvania and a Bachelor of Science degree in biology from Duke University.